Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Rotman Research Institute at Baycrest H. Lundbeck A/S |
---|---|
Information provided by: | Rotman Research Institute at Baycrest |
ClinicalTrials.gov Identifier: | NCT00594737 |
Memantine has been approved for use in Alzheimer's disease. Its mechanism of action raises questions of whether it can also be effective for non-Alzheimer's dementias such as frontotemporal dementia (FTD), which currently has no disease-modifying treatment.
This is an open-label study to probe the effects of memantine in 12 outpatients diagnosed with FTD, as shown objectively by comparing PET scans performed before and after use of the medication. The specific type of PET scan, FDG-PET, allows us to gauge the effects of memantine on cortical activity levels. We hypothesize that subjects on memantine will show normalization of cortical metabolic activity.
Condition | Intervention | Phase |
---|---|---|
Frontotemporal Dementia |
Drug: memantine hydrochloride |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia |
Estimated Enrollment: | 15 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 40 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Tiffany Chow, MD | 416-785-2500 ext 3459 | tchow@rotman-baycrest.on.ca |
Contact: Morris Freedman, MD, FRCPC | 416-785-2444 |
Canada, Ontario | |
Baycrest | Recruiting |
Toronto, Ontario, Canada, M6A 2E1 | |
Principal Investigator: Tiffany W Chow, MD |
Principal Investigator: | Tiffany W Chow, MD | Rotman Research Institute at Baycrest, University of Toronto |
Responsible Party: | Rotman Research Institute at Baycrest, University of Toronto ( Tiffany Chow, MD, Principal Investigator ) |
Study ID Numbers: | Baycrest.Ebixa.FTD-001, Lundbeck 11627A |
Study First Received: | January 7, 2008 |
Last Updated: | January 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00594737 |
Health Authority: | Canada: Health Canada |
PET frontotemporal dementia memantine Pick's disease |
Excitatory Amino Acids Pick Disease of the Brain Speech Disorders Frontotemporal dementia Aphasia Central Nervous System Diseases Language Disorders Brain Diseases Aphasia, Primary Progressive Cognition Disorders Signs and Symptoms Dopamine |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Memantine Neurologic Manifestations Lobar atrophy of brain Primary progressive aphasia Dementia Neurobehavioral Manifestations Pick disease of the brain Communication Disorders Delirium |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Antiparkinson Agents Excitatory Amino Acid Agents Dopamine Agents Central Nervous System Agents Pharmacologic Actions Excitatory Amino Acid Antagonists |